IM Ziprasidone (Geodon) Dosing
The recommended intramuscular dose of ziprasidone is 10-20 mg per injection, with 20 mg being the most effective dose for acute agitation, administered every 2-4 hours as needed, with a maximum daily dose of 40 mg. 1
Standard Dosing Regimen
Initial and Repeat Dosing:
- 10 mg IM is the standard starting dose, though 20 mg demonstrates superior efficacy 1, 2
- 20 mg IM is the optimal dose based on Class II evidence showing significantly greater reduction in agitation compared to lower doses 2
- Doses can be repeated every 2-4 hours as needed 2, 1
- Maximum daily dose: 40 mg (typically achieved through 2 doses of 20 mg) 1
Dose-Response Evidence
The evidence clearly demonstrates a dose-dependent effect:
- 20 mg dose: Most effective, with statistically significant reduction in agitation scores at 30 minutes post-dose 2
- 10 mg dose: Moderately effective, showing significant reduction at 15 minutes compared to 2 mg control 2, 3
- 2 mg dose: Used only as control/placebo equivalent in trials, not therapeutically effective 2, 1
Clinical Efficacy Timeline
- Peak effect: 15-30 minutes after injection 2, 3
- Peak serum concentration: Approximately 60 minutes or earlier 1
- Half-life: 2-5 hours for IM administration 1
- Bioavailability: 100% (compared to 60% for oral formulation) 1
Comparative Effectiveness
Ziprasidone IM demonstrates superior tolerability compared to haloperidol:
- Lower incidence of movement disorders (extrapyramidal symptoms, dystonia, akathisia) 2, 4
- Reduced need for anticholinergic medications 4
- No excessive sedation, respiratory depression, or bradycardia at therapeutic doses 5
- Comparable efficacy to haloperidol 5 mg + lorazepam 2 mg for acute agitation 2
Safety Considerations
Important caveats:
- All antipsychotics, including ziprasidone, prolong QTc interval, though none exceeded 500 ms in studies 2
- Avoid in patients with anticholinergic or sympathomimetic toxicity, as ziprasidone may exacerbate agitation 2
- Can be safely co-administered with lorazepam without increased adverse effects 5
- Minimal extrapyramidal symptoms reported (one case of akathisia in trials with 10 mg dose) 3
Transition to Oral Therapy
Following IM stabilization (typically 1-3 days):
- Transition to oral ziprasidone 80-200 mg/day in divided doses 1, 4
- Oral formulation requires food for optimal absorption (bioavailability increases 2-fold with food) 1
- Transition is well-tolerated with continued symptom control 4, 5
Special Populations
Pediatric dosing (limited evidence):
- 0.2 mg/kg IM may be more effective than lower doses (0.13 mg/kg) in pediatric emergency settings 6
- This represents off-label use with limited safety data in children